Soligenix: Late-Stage Biopharma Addressing a $2 Billion Opportunity

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases with unmet medical needs. The Company's primary focus is on its Specialized BioTherapeutics business segment, which is responsible for the development of HyBryte™, a novel photodynamic therapy that uses safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The Company has successfully completed a Phase 3 study for HyBryte™ and is now negotiating a confirmatory Phase 3 pivotal study design with the US Food & Drug Administration, while also evaluating/pursuing potential HyBryte™ marketing approval ex-U.S. with the successfully completed Phase 3 study. Visit SNGXinfo.com to learn more. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. Soligenix (SNGX) is a client of RedChip Companies, Inc. SNGX agreed to pay RedChip Companies, Inc. 50,000 shares of Rule 144 stock, deemed earned immediately, and a monthly cash fee of $10,000, beginning in April 2023, for 12 months of RedChip investor awareness services. SNGX also agreed to pay RedChip a one-time fifty-thousand dollar fee for a 10 day national TV ad campaign aired June 12 through June 25, 2024. For full disclosure, visit RedChip.com/disclosures.